Beiersdorf


CARE+ weighing

19/03/19 -"We have taken the CARE+ related additional costs into account. Additionally, we have started to factor in the guidance regarding working capital and the income tax rate, but expect them to be more ..."

Pages
57
Language
English
Published on
19/03/19
You may also be interested by these reports :
19/04/24
L’Oréal has once again reported a strong start to the year, with all divisions exceeding expectations. The robust demand from global consumers for ...

16/04/24
Beiersdorf seems to be back to a long(er) term growth, having reported strong growth in Nivea and Eucerin/Aquaphor, while tesa posted the expected ...

15/04/24
Notably, since its demerger, Haleon has remained focused on reducing its debt (2023 adjusted net debt/EBITDA of 2.9x vs. 3.5x in 2022), thanks to ...

03/04/24
We have updated the EBIT estimates used in our NAV valuation, as our previous figures were outdated. We now use a 2 year average of our forecasts and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO